TABLE 2 Incidence of drug-induced diarrhea in phase I–III studies of molecular-targeted cancer drugs.
From the following article:
Drug Insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy
Yohann Loriot, Gabriel Perlemuter, David Malka, Frédérique Penault-Lorca, Valérie Boige, Eric Deutsch, Christophe Massard, Jean Pierre Armand and Jean-Charles Soria
BACK TO ARTICLE| Drug | Incidence of diarrhea (%) | Reference |
|---|---|---|
aDrug used in combination with cytotoxic chemotherapy. | ||
| Erlotinib | 55 (6% grade 3–5)
68 (12% grade 3–4)a | Shepherd et al. (2005)2 Herbst et al. (2005)65 |
| Gefitinib | 40–60 (8% grade 2)
58 (3% grade 3–4)a | Fukuoka et al. (2003)3 Herbst et al. (2004)66 |
| Lapatinib | 40 (10% grade 3)
60 (13% grade 3–4) | Burrhis et al. (2005)24 Geyer et al. (2006)67 |
| HKI-272 | 84 | Wong et al. (2006)19 |
| Sorafenib | 33 (24% grade 2–3) | Escudier et al. (2005)10 |
| Sunitinib | 20 (grade 2–3) | Motzer et al. (2006)11 |
| Imatinib | 45 | Demetri et al. (2002)14 |
| Flavopiridol | 50 | Liu et al. (2004)15 |
| Bortezomib | 32 (8% grade 3–4)
29 (9% grade 3–4) | Fanucchi et al. (2003)34 |